ARS Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

• ARS Pharmaceuticals Inc SPRY.OQ reported quarterly adjusted earnings of 49 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -7 cents. The mean expectation of five analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -31 cents to 28 cents per share.

• Revenue was $86.58 million​; analysts expected $15.82 million.

• ARS Pharmaceuticals Inc's reported EPS for the quarter was 49 cents​.

• The company reported quarterly net income of $49.93 million.

• ARS Pharmaceuticals Inc shares had risen by 10.4% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 5.1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $31.50

This summary was machine generated from LSEG data March 20 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)